Literature DB >> 7942994

Molecular-neurobehavioral associations in females with the fragile X full mutation.

M T Abrams1, A L Reiss, L S Freund, T L Baumgardner, G A Chase, M B Denckla.   

Abstract

In this study, young females with the fragile X [fra(X)] full mutation (fM) were assessed using quantitative measures of mutation amplification size (Amp) as well as the ratio of active normal X chromosome to total normal X chromosome (activation ratio-AR). Neurobehavioral assessments of females with the fM were performed and included specific and general measures of cognitive and behavioral/developmental functioning. To investigate molecular-behavioral associations, Amp and AR were used as independent variables, while cognitive and behavioral scores were used as dependent variables. Significant correlations were observed between both molecular variables (Amp and AR) and measures of cognitive functioning, with AR showing the most consistent and robust correlations. As AR increased, overall IQ and specific subtest and area scores from the cognitive tests increased. Conversely, as Amp increased, the overall IQ and specific subtest and area cognitive scores decreased. No significant associations were observed between AR or Amp and measures of behavior or development. The molecular-cognitive associations were generally consistent with the cognitive profile previously described in studies comparing females with fra(X) to age-matched controls. Amp and AR were not associated with one another, nor were they associated with the same cluster of cognitive measures. Though this report does not conclusively show that AR and Amp can be used to clinically assess the risk of a female with the fM for cognitive disability, the evidence presented does suggest that these molecular variables, especially AR, reflect important underlying genetic factors contributing to the fra(X) phenotype.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7942994     DOI: 10.1002/ajmg.1320510407

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  14 in total

1.  Resolution of spatial and temporal visual attention in infants with fragile X syndrome.

Authors:  Faraz Farzin; Susan M Rivera; David Whitney
Journal:  Brain       Date:  2011-11       Impact factor: 13.501

2.  Mental status of females with an FMR1 gene full mutation.

Authors:  B B de Vries; A M Wiegers; A P Smits; S Mohkamsing; H J Duivenvoorden; J P Fryns; L M Curfs; D J Halley; B A Oostra; A M van den Ouweland; M F Niermeijer
Journal:  Am J Hum Genet       Date:  1996-05       Impact factor: 11.025

Review 3.  Fragile X syndrome. Molecular and clinical insights and treatment issues.

Authors:  R J Hagerman
Journal:  West J Med       Date:  1997-02

4.  Mapping of an origin of DNA replication in the promoter of fragile X gene FMR1.

Authors:  Bruna P Brylawski; Paul D Chastain; Stephanie M Cohen; Marila Cordeiro-Stone; David G Kaufman
Journal:  Exp Mol Pathol       Date:  2006-12-28       Impact factor: 3.362

5.  Skewed X inactivation of the normal allele in fully mutated female carriers determines the levels of FMRP in blood and the fragile X phenotype.

Authors:  Raquel Martínez; Victoria Bonilla-Henao; Antonio Jiménez; Miguel Lucas; Carmen Vega; Inmaculada Ramos; Francisco Sobrino; Elizabeth Pintado
Journal:  Mol Diagn       Date:  2005

6.  Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment.

Authors:  Walter E Kaufmann; Sharon A Kidd; Howard F Andrews; Dejan B Budimirovic; Amy Esler; Barbara Haas-Givler; Tracy Stackhouse; Catharine Riley; Georgina Peacock; Stephanie L Sherman; W Ted Brown; Elizabeth Berry-Kravis
Journal:  Pediatrics       Date:  2017-06       Impact factor: 7.124

7.  FORWARD: A Registry and Longitudinal Clinical Database to Study Fragile X Syndrome.

Authors:  Stephanie L Sherman; Sharon A Kidd; Catharine Riley; Elizabeth Berry-Kravis; Howard F Andrews; Robert M Miller; Sharyn Lincoln; Mark Swanson; Walter E Kaufmann; W Ted Brown
Journal:  Pediatrics       Date:  2017-06       Impact factor: 7.124

8.  Prevalence, nature, and correlates of sleep problems among children with fragile X syndrome based on a large scale parent survey.

Authors:  Rebecca Kronk; Ellen E Bishop; Melissa Raspa; Julie O Bickel; Daniel A Mandel; Donald B Bailey
Journal:  Sleep       Date:  2010-05       Impact factor: 5.849

Review 9.  Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.

Authors:  John A Tsiouris; W Ted Brown
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 10.  Autism: the point of view from fragile X studies.

Authors:  C Feinstein; A L Reiss
Journal:  J Autism Dev Disord       Date:  1998-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.